Cargando…

The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer

BACKGROUND: Oestrogen receptor (ER) status provides invaluable prognostic and therapeutic information in breast cancer (BC). When clinical decision making is driven by ER status, the value of progesterone receptor (PgR) status is less certain. The aim of this study was to describe clinicopathologica...

Descripción completa

Detalles Bibliográficos
Autores principales: Davey, M G, Ryan, É J, Folan, P J, O’Halloran, N, Boland, M R, Barry, M K, Sweeney, K J, Malone, C M, McLaughlin, R J, Kerin, M J, Lowery, A J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134515/
https://www.ncbi.nlm.nih.gov/pubmed/34013318
http://dx.doi.org/10.1093/bjsopen/zrab040
_version_ 1783695190417997824
author Davey, M G
Ryan, É J
Folan, P J
O’Halloran, N
Boland, M R
Barry, M K
Sweeney, K J
Malone, C M
McLaughlin, R J
Kerin, M J
Lowery, A J
author_facet Davey, M G
Ryan, É J
Folan, P J
O’Halloran, N
Boland, M R
Barry, M K
Sweeney, K J
Malone, C M
McLaughlin, R J
Kerin, M J
Lowery, A J
author_sort Davey, M G
collection PubMed
description BACKGROUND: Oestrogen receptor (ER) status provides invaluable prognostic and therapeutic information in breast cancer (BC). When clinical decision making is driven by ER status, the value of progesterone receptor (PgR) status is less certain. The aim of this study was to describe clinicopathological features of ER-positive (ER+)/PgR-negative (PgR-) BC and to determine the effect of PgR negativity in ER+ disease. METHODS: Consecutive female patients with ER+ BC from a single institution were included. Factors associated with PgR- disease were assessed using binary logistic regression. Oncological outcome was assessed using Kaplan–Meier and Cox regression analysis. RESULTS: In total, 2660 patients were included with a mean(s.d.) age of 59.6(13.3) years (range 21–99 years). Median follow-up was 97.2 months (range 3.0–181.2). Some 2208 cases were PgR+ (83.0 per cent) and 452 were PgR- (17.0 per cent). Being postmenopausal (odds ratio (OR) 1.66, 95 per cent c.i. 1.25 to 2.20, P < 0.001), presenting with symptoms (OR 1.71, 95 per cent c.i. 1.30 to 2.25, P < 0.001), ductal subtype (OR 1.51, 95 per cent c.i. 1.17 to 1.97, P = 0.002) and grade 3 tumours (OR 2.20, 95 per cent c.i. 1.68 to 2.87, P < 0.001) were all associated with PgR negativity. In those receiving neoadjuvant chemotherapy (308 patients), pathological complete response rates were 10.1 per cent (25 of 247 patients) in patients with PgR+ disease versus 18.0 per cent in PgR- disease (11 of 61) (P = 0.050). PgR negativity independently predicted worse disease-free (hazard ratio (HR) 1.632, 95 per cent c.i. 1.209 to 2.204, P = 0.001) and overall survival (HR 1.774, 95 per cent c.i. 1.324 to 2.375, P < 0.001), as well as worse overall survival in ER+/HER2- disease (P = 0.004). CONCLUSIONS: In ER+ disease, PgR- tumours have more aggressive clinicopathological features and worse oncological outcomes. Neoadjuvant and adjuvant therapeutic strategies should be tailored according to PgR status.
format Online
Article
Text
id pubmed-8134515
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-81345152021-05-25 The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer Davey, M G Ryan, É J Folan, P J O’Halloran, N Boland, M R Barry, M K Sweeney, K J Malone, C M McLaughlin, R J Kerin, M J Lowery, A J BJS Open Original Article BACKGROUND: Oestrogen receptor (ER) status provides invaluable prognostic and therapeutic information in breast cancer (BC). When clinical decision making is driven by ER status, the value of progesterone receptor (PgR) status is less certain. The aim of this study was to describe clinicopathological features of ER-positive (ER+)/PgR-negative (PgR-) BC and to determine the effect of PgR negativity in ER+ disease. METHODS: Consecutive female patients with ER+ BC from a single institution were included. Factors associated with PgR- disease were assessed using binary logistic regression. Oncological outcome was assessed using Kaplan–Meier and Cox regression analysis. RESULTS: In total, 2660 patients were included with a mean(s.d.) age of 59.6(13.3) years (range 21–99 years). Median follow-up was 97.2 months (range 3.0–181.2). Some 2208 cases were PgR+ (83.0 per cent) and 452 were PgR- (17.0 per cent). Being postmenopausal (odds ratio (OR) 1.66, 95 per cent c.i. 1.25 to 2.20, P < 0.001), presenting with symptoms (OR 1.71, 95 per cent c.i. 1.30 to 2.25, P < 0.001), ductal subtype (OR 1.51, 95 per cent c.i. 1.17 to 1.97, P = 0.002) and grade 3 tumours (OR 2.20, 95 per cent c.i. 1.68 to 2.87, P < 0.001) were all associated with PgR negativity. In those receiving neoadjuvant chemotherapy (308 patients), pathological complete response rates were 10.1 per cent (25 of 247 patients) in patients with PgR+ disease versus 18.0 per cent in PgR- disease (11 of 61) (P = 0.050). PgR negativity independently predicted worse disease-free (hazard ratio (HR) 1.632, 95 per cent c.i. 1.209 to 2.204, P = 0.001) and overall survival (HR 1.774, 95 per cent c.i. 1.324 to 2.375, P < 0.001), as well as worse overall survival in ER+/HER2- disease (P = 0.004). CONCLUSIONS: In ER+ disease, PgR- tumours have more aggressive clinicopathological features and worse oncological outcomes. Neoadjuvant and adjuvant therapeutic strategies should be tailored according to PgR status. Oxford University Press 2021-05-20 /pmc/articles/PMC8134515/ /pubmed/34013318 http://dx.doi.org/10.1093/bjsopen/zrab040 Text en © The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Article
Davey, M G
Ryan, É J
Folan, P J
O’Halloran, N
Boland, M R
Barry, M K
Sweeney, K J
Malone, C M
McLaughlin, R J
Kerin, M J
Lowery, A J
The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
title The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
title_full The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
title_fullStr The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
title_full_unstemmed The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
title_short The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
title_sort impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8134515/
https://www.ncbi.nlm.nih.gov/pubmed/34013318
http://dx.doi.org/10.1093/bjsopen/zrab040
work_keys_str_mv AT daveymg theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT ryanej theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT folanpj theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT ohallorann theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT bolandmr theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT barrymk theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT sweeneykj theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT malonecm theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT mclaughlinrj theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT kerinmj theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT loweryaj theimpactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT daveymg impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT ryanej impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT folanpj impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT ohallorann impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT bolandmr impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT barrymk impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT sweeneykj impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT malonecm impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT mclaughlinrj impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT kerinmj impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer
AT loweryaj impactofprogesteronereceptornegativityononcologicaloutcomesinoestrogenreceptorpositivebreastcancer